Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma
Phase 1/2 Terminated
53 enrolled 22 charts
A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Participants With Newly Diagnosed or Recurrent Glioblastoma
Phase 1/2 Completed
116 enrolled 31 charts
Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors
Phase 1/2 Completed
160 enrolled 21 charts
Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma
Phase 1/2 Completed
65 enrolled 21 charts
AXL1717
Phase 1/2 Terminated
10 enrolled 8 charts
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase 1/2 Completed
125 enrolled 12 charts
RTOG 0913
Phase 1/2 Completed
279 enrolled 14 charts
Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab
Phase 1/2 Completed
121 enrolled 27 charts
Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma
Phase 1/2 Completed
79 enrolled 17 charts
Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM)
Phase 1/2 Terminated
21 enrolled 8 charts
Phase 1/2 Study of Enzastaurin in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients
Phase 1/2 Completed
72 enrolled 19 charts
Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Phase 1/2 Completed
122 enrolled 11 charts
Dasatinib or Placebo, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase 1/2 Completed
217 enrolled 12 charts
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
Phase 1/2 Completed
25 enrolled 14 charts
Hydroxychloroquine, Radiation, and Temozolomide Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase 1/2 Completed
92 enrolled 18 charts
Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma
Phase 1/2 Terminated
12 enrolled 7 charts
Tetra-O-Methyl Nordihydroguaiaretic Acid in Treating Patients With Recurrent High-Grade Glioma
Phase 1/2 Completed
35 enrolled 13 charts
Zactima
Phase 1/2 Completed
119 enrolled 15 charts
Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma
Phase 1/2 Completed
30 enrolled 11 charts
Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
Phase 1/2 Completed
92 enrolled 24 charts
Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Glioblastoma
Phase 1/2 Terminated
43 enrolled 22 charts
Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme
Phase 1/2 Completed
116 enrolled 17 charts
Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
Phase 1/2 Completed
118 enrolled 10 charts
A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade Gliomas
Phase 1/2 Completed
57 enrolled 18 charts
Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma
Phase 1/2 Completed
136 enrolled 27 charts
Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma
Phase 1/2 Completed
257 enrolled 16 charts
Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma
Phase 1/2 Completed
60 enrolled 22 charts
FR901228 in Treating Patients With Recurrent High-Grade Gliomas
Phase 1/2 Completed
50 enrolled 6 charts
Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase 1/2 Completed
112 enrolled 14 charts
Everolimus and Gefitinib in Treating Patients With Progressive Glioblastoma Multiforme or Progressive Metastatic Prostate Cancer
Phase 1/2 Completed
61 enrolled 8 charts
RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant Glioma
Phase 1/2 Terminated
13 enrolled 13 charts
Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma
Phase 1/2 Completed
69 enrolled 12 charts